unique patented adjuvants
In order to achieve strong immune response to the desired antigen (i.e. when preparing specific hyperimmune serum), of critical importance are several steps in the humoral response cascade: effective delivery of antigen to Dendritic /antigen presenting cell (1), effective processing of the antigen by dendritic cell and antigen presentation (2), and the strong stimulation of helper T-cells (3). Of additional importance is an effective presentation of the antigen by dendritic cells to B-cells, - this leads to the production of high affinity antibodies
Over the last 10 years we have released two unique adjuvants, involving patented technology:
IMMACCEL-R
New adjuvant allowing to greatly accelerate immune response to an antigen in a T-cell dependent manner, Leads to early selection of high -affinity antibodies, isotype-switch from IgM to IgM. More....
MAD
Enhances delivery of Antigen to Dendritic cells, promotes its processing in Dendritic cells, augments T-helper response to antigen, improves B-cell maturation. As a result titre of antibody may be improved up to 30 times for low immunogenicity antigens (as compared to Freund adjuvant. More...
Now we offer new enhanced Custom Antibody protocol that combines the benefits of both adjuvants. It is available only from us or from POCONO Rabbit Farm
You can also order just adjuvants, species-specific, and use them in your own facilities. Standing order and Volume discount are available for animal facilities and companies
These adjuvants allowed us to create two unique Custom Antibody Protocol that we offered to customer via our former company, PickCell Laboratories BV:
Express Rabbit (hyperimmune serum in 28 days)
The Protocols were so successful (see the references on the right) that resulted in appearance on the market of a number of copy-cat protocols (we did not licensed the technology, so we believe these were just copying the idea)
Mighty Rabbit (high titre serum)
The Protocols were so successful (see the references on the right) that resulted in appearance on the market of a number of copy-cat protocols (we did not licensed the technology, so we believe these were just copying the idea)
